Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ruxolitinib monotherapy Variant #06 Partial | — | R 48 520 | — | — | — | ~1 | ~R 48 520 PFS proxy · indirect | 2 |
Pomalidomide and Prednisone Variant #01 | — | R 4 840 | 28d | — | — | ~4 | ~R 19 186 indirect | — |
Pomalidomide monotherapy Variant #01 | — | R 4 782 | 28d | ~2.7 mo | — | ~2 | ~R 9 564 PFS proxy · indirect | 1 |
Lenalidomide monotherapy Variant #01 | — | R 2 178 | 28d | ~39.0 mo | ~113.8 mo | ~24 | ~R 52 272 PFS proxy · indirect | 10 |
Danazol monotherapy Variant #01 | — | R 1 870 | 112d | — | — | ~1 | ~R 1 870 indirect | — |
Hydroxyurea monotherapy Variant #01 | — | R 265 | 28d | — | ~243.6 mo | ~2 | ~R 529 PFS proxy · indirect | — |
Prednisone monotherapy Variant #11 Partial | — | R 39 | 7d | ~2.2 mo | ~14.1 mo | ~1 | ~R 39 PFS proxy · indirect | 8 |
Placebo Partial | — | — | — | ~4.2 mo | ~8.0 mo | — | — | 145 |
Fedratinib monotherapy Variant #01 Partial | — | — | 28d | — | — | ~2 | — | — |
Pacritinib monotherapy Variant #01 Partial | — | — | 28d | — | — | ~2 | — | — |
10 of 10 regimens shown